Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
Aug 29, 2023

Virtual presentation to be available starting on September 11, 2023, at 7 AM Eastern Time TEL AVIV, Israel, Aug. 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a...

Aug 14, 2023

─On Track to Achieve CM-101 PSC Phase 2 Readout Expected in 2H2024— ─Extended Estimated Cash Runway Through PSC Readout and 2024 Year-End─ ─Reported Positive Secondary Analysis of Data...

Jun 28, 2023

--Includes Extensive Data Showing that CM-101, Chemomab's CCL24-Neutralizing Antibody, Interrupts the Fibro-Inflammatory Processes that Lead to PSC-- TEL AVIV, Israel, June 28, 2023 /PRNewswire/...

Jun 26, 2023

--New Proteomics Data Further Confirms the Relationship between CM-101's CCL24 Target and Primary Sclerosing Cholangitis (PSC) Disease Pathways-- --Provides Further Evidence that CM-101 Interrupts...

All News

Stock Info
Monday, September 11, 2023 - Thursday, September 14, 2023

September 11, 2023

One-on-one virtual meetings with Chemomab Management

Register to meet at https://hcwevents.com/annualconference/

Monday, August 14, 2023
8:00am EDT

A press release including financial tables and a corporate update will be issued at 8:00 am Eastern Time, Monday, August 14, 2023

Investors who have questions about the Second Quarter results are welcome to contact the company after issuance of the press release at ir@chemomab.com

All Events

Featured Presentations


Chemomab Corporate Overview - September 2023


Annual Report


Chemomab 2022 Annual Report